Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“At NACLC25 sharing our poster on time toxicity differences between FLAURA2 and MARIPOSA in EGFR lung cancer.
As therapies evolve, we must ensure the patient experience evolves with them. Time is a vital part of treatment burden.”

More posts featuring Narjust Florez on OncoDaily.